Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.

Schoenfeld AJ, Rizvi H, Bandlamudi C, Sauter JL, Travis WD, Rekhtman N, Plodkowski AJ, Perez-Johnston R, Sawan P, Beras A, Egger JV, Ladanyi M, Arbour KC, Rudin CM, Riely GJ, Taylor BS, Donoghue MTA, Hellmann MD.

Ann Oncol. 2020 Feb 6. pii: S0923-7534(20)36018-X. doi: 10.1016/j.annonc.2020.01.065. [Epub ahead of print]

PMID:
32178965
2.

Irrigation of Zea mays with UASB-treated textile wastewater; effect on early irrigation of Zea mays with UASB-treated textile wastewater; effect on early growth and physiology.

Younas S, Rizvi H, Ali S, Abbas F.

Environ Sci Pollut Res Int. 2020 Feb 19. doi: 10.1007/s11356-020-07948-5. [Epub ahead of print]

PMID:
32077022
3.

Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50.

Gainor JF, Rizvi H, Jimenez Aguilar E, Skoulidis F, Yeap BY, Naidoo J, Khosrowjerdi S, Mooradian M, Lydon C, Illei P, Zhang J, Peterson R, Ricciuti B, Nishino M, Zhang J, Roth JA, Grishman J, Anderson D, Little BP, Carter BW, Arbour K, Sauter JL, Mino-Kenudson M, Heymach JV, Digumarthy S, Shaw AT, Awad MM, Hellmann MD.

Ann Oncol. 2020 Mar;31(3):404-411. doi: 10.1016/j.annonc.2019.11.015. Epub 2019 Dec 9.

4.

Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC.

Hellmann MD, Nabet BY, Rizvi H, Chaudhuri AA, Wells DK, Dunphy MP, Chabon JJ, Liu CL, Hui AB, Arbour KC, Luo J, Preeshagul IR, Moding EJ, Almanza D, Bonilla RF, Sauter JL, Choi H, Tenet M, Abu-Akeel M, Plodkowski AJ, Perez-Johnston R, Yoo CH, Ko RB, Stehr H, Gojenola L, Wakelee HA, Padda SK, Neal JW, Chaft JE, Kris MG, Rudin CM, Merghoub T, Li BT, Alizadeh AA, Diehn M.

Clin Cancer Res. 2020 Feb 11. pii: clincanres.3418.2019. doi: 10.1158/1078-0432.CCR-19-3418. [Epub ahead of print]

PMID:
32046999
5.

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.

Schoenfeld AJ, Chan JM, Kubota D, Sato H, Rizvi H, Daneshbod Y, Chang JC, Paik PK, Offin M, Arcila ME, Davare MA, Shinde U, Pe'er D, Rekhtman N, Kris MG, Somwar R, Riely GJ, Ladanyi M, Yu HA.

Clin Cancer Res. 2020 Jan 7. pii: clincanres.3563.2019. doi: 10.1158/1078-0432.CCR-19-3563. [Epub ahead of print]

PMID:
31911548
6.

Insecticidal, biological and biochemical response of Musca domestica (Diptera: Muscidae) to some indigenous weed plant extracts.

Attaullah, Zahoor MK, Zahoor MA, Mubarik MS, Rizvi H, Majeed HN, Zulhussnain M, Ranian K, Sultana K, Imran M, Qamer S.

Saudi J Biol Sci. 2020 Jan;27(1):106-116. doi: 10.1016/j.sjbs.2019.05.009. Epub 2019 May 29.

7.

Comprehensive facts on dynamic antimicrobial properties of polysaccharides and biomolecules-silver nanoparticle conjugate.

Irshad A, Sarwar N, Sadia H, Malik K, Javed I, Irshad A, Afzal M, Abbas M, Rizvi H.

Int J Biol Macromol. 2020 Feb 15;145:189-196. doi: 10.1016/j.ijbiomac.2019.12.089. Epub 2019 Dec 12. Review.

PMID:
31838065
8.

Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer.

Vokes NI, Liu D, Ricciuti B, Jimenez-Aguilar E, Rizvi H, Dietlein F, He MX, Margolis CA, Elmarakeby HA, Girshman J, Adeni A, Sanchez-Vega F, Schultz N, Dahlberg S, Zehir A, Jänne PA, Nishino M, Umeton R, Sholl LM, Van Allen EM, Hellmann MD, Awad MM.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00171. Epub 2019 Nov 12.

9.

B Cell Synovitis and Clinical Phenotypes in Rheumatoid Arthritis: Relationship to Disease Stages and Drug Exposure.

Rivellese F, Humby F, Bugatti S, Fossati-Jimack L, Rizvi H, Lucchesi D, Lliso-Ribera G, Nerviani A, Hands RE, Giorli G, Frias B, Thorborn G, Jaworska E, John C, Goldmann K, Lewis MJ, Manzo A, Bombardieri M, Pitzalis C; PEAC-R4RA Investigators.

Arthritis Rheumatol. 2019 Nov 29. doi: 10.1002/art.41184. [Epub ahead of print]

PMID:
31785084
10.

Novel markers in pediatric-type follicular lymphoma.

Agostinelli C, Akarca AU, Ramsay A, Rizvi H, Rodriguez-Justo M, Pomplun S, Proctor I, Sabattini E, Linch D, Daw S, Pittaluga S, Pileri SA, Jaffe ES, Quintanilla-Martinez L, Marafioti T.

Virchows Arch. 2019 Dec;475(6):771-779. doi: 10.1007/s00428-019-02681-y. Epub 2019 Nov 4.

11.

Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade.

Osorio JC, Arbour KC, Le DT, Durham JN, Plodkowski AJ, Halpenny DF, Ginsberg MS, Sawan P, Crompton JG, Yu HA, Namakydoust A, Nabet BY, Chaft JE, Riely GJ, Rizvi H, Diaz LA Jr, Hellmann MD.

J Clin Oncol. 2019 Dec 20;37(36):3546-3555. doi: 10.1200/JCO.19.00709. Epub 2019 Nov 1.

PMID:
31675272
12.

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.

Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, Nishino M, Sholl LM, Adeni A, Subegdjo S, Khosrowjerdi S, Peterson RM, Digumarthy S, Liu C, Sauter J, Rizvi H, Arbour KC, Carter BW, Heymach JV, Altan M, Hellmann MD, Awad MM.

Ann Oncol. 2019 Oct 1;30(10):1653-1659. doi: 10.1093/annonc/mdz288.

PMID:
31435660
13.

Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.

Offin M, Chan JM, Tenet M, Rizvi HA, Shen R, Riely GJ, Rekhtman N, Daneshbod Y, Quintanal-Villalonga A, Penson A, Hellmann MD, Arcila ME, Ladanyi M, Pe'er D, Kris MG, Rudin CM, Yu HA.

J Thorac Oncol. 2019 Oct;14(10):1784-1793. doi: 10.1016/j.jtho.2019.06.002. Epub 2019 Jun 19.

PMID:
31228622
14.

Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer.

Hu-Lieskovan S, Lisberg A, Zaretsky JM, Grogan TR, Rizvi H, Wells DK, Carroll J, Cummings A, Madrigal J, Jones B, Gukasyan J, Shintaku IP, Slamon D, Dubinett S, Goldman JW, Elashoff D, Hellmann MD, Ribas A, Garon EB.

Clin Cancer Res. 2019 Aug 15;25(16):5061-5068. doi: 10.1158/1078-0432.CCR-18-4275. Epub 2019 May 21.

15.

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.

Hastings K, Yu HA, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K.

Ann Oncol. 2019 Aug 1;30(8):1311-1320. doi: 10.1093/annonc/mdz141.

16.

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.

Schoenfeld AJ, Arbour KC, Rizvi H, Iqbal AN, Gadgeel SM, Girshman J, Kris MG, Riely GJ, Yu HA, Hellmann MD.

Ann Oncol. 2019 May 1;30(5):839-844. doi: 10.1093/annonc/mdz077.

PMID:
30847464
17.

Epigenetic Regulation of iASPP-p63 Feedback Loop in Cutaneous Squamous Cell Carcinoma.

Robinson DJ, Patel A, Purdie KJ, Wang J, Rizvi H, Hufbauer M, Ostano P, Akgül B, Chiorino G, Harwood CA, Bergamaschi D.

J Invest Dermatol. 2019 Aug;139(8):1658-1671.e8. doi: 10.1016/j.jid.2019.01.020. Epub 2019 Jan 30.

PMID:
30710576
18.

Brentuximab vedotin in multifocal cutaneous anaplastic large cell lymphoma in a patient with human immunodeficiency virus following Hodgkin lymphoma.

Wolf S, Goiriz R, Dhairyawan R, Paige D, Rizvi H, Haroon A, Montoto S.

Clin Exp Dermatol. 2019 Jul;44(5):562-564. doi: 10.1111/ced.13824. Epub 2018 Nov 14. No abstract available.

PMID:
30430604
19.

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection.

Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson DB, Rizvi HA, Joshua AM, Hellmann MD, Long GV, Menzies AM.

Eur J Cancer. 2018 Nov;104:137-144. doi: 10.1016/j.ejca.2018.09.017. Epub 2018 Oct 20.

PMID:
30347289
20.

The Role of Human Papillomaviruses and Polyomaviruses in BRAF-Inhibitor Induced Cutaneous Squamous Cell Carcinoma and Benign Squamoproliferative Lesions.

Purdie KJ, Proby CM, Rizvi H, Griffin H, Doorbar J, Sommerlad M, Feltkamp MC, der Meijden EV, Inman GJ, South AP, Leigh IM, Harwood CA.

Front Microbiol. 2018 Aug 14;9:1806. doi: 10.3389/fmicb.2018.01806. eCollection 2018.

21.

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.

Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martínez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, Sabari JK, Caramella C, Plodkowski AJ, Halpenny D, Chaft JE, Planchard D, Riely GJ, Besse B, Hellmann MD.

J Clin Oncol. 2018 Oct 1;36(28):2872-2878. doi: 10.1200/JCO.2018.79.0006. Epub 2018 Aug 20.

PMID:
30125216
22.

Maternal protein restriction induces gastrointestinal dysfunction and enteric nervous system remodeling in rat offspring.

Aubert P, Oleynikova E, Rizvi H, Ndjim M, Le Berre-Scoul C, Grohard PA, Chevalier J, Segain JP, Le Drean G, Neunlist M, Boudin H.

FASEB J. 2019 Jan;33(1):770-781. doi: 10.1096/fj.201800079R. Epub 2018 Aug 1.

PMID:
30067379
23.

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.

Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li BT, Drilon A, Kris MG, Rudin CM, Schultz N, Arcila ME, Ladanyi M, Riely GJ, Yu H, Hellmann MD.

Clin Cancer Res. 2019 Feb 1;25(3):1063-1069. doi: 10.1158/1078-0432.CCR-18-1102. Epub 2018 Jul 25.

24.

Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.

Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M, Wilkins O, Panora E, Halpenny DF, Long NM, Kris MG, Rudin CM, Chaft JE, Hellmann MD.

Cancer Immunol Res. 2018 Sep;6(9):1093-1099. doi: 10.1158/2326-6066.CIR-17-0755. Epub 2018 Jul 10.

25.

Next-generation sequencing based detection of germline and somatic alterations in a patient with four metachronous primary tumors.

Martin M, Sabari JK, Turashvili G, Halpenny DF, Rizvi H, Shapnik N, Makker V.

Gynecol Oncol Rep. 2018 Apr 18;24:94-98. doi: 10.1016/j.gore.2018.04.004. eCollection 2018 May.

26.

The Undergraduate Training in Genomics (UTRIG) Initiative: early & active training for physicians in the genomic medicine era.

Wilcox RL, Adem PV, Afshinnekoo E, Atkinson JB, Burke LW, Cheung H, Dasgupta S, DeLaGarza J, Joseph L, LeGallo R, Lew M, Lockwood CM, Meiss A, Norman J, Markwood P, Rizvi H, Shane-Carson KP, Sobel ME, Suarez E, Tafe LJ, Wang J, Haspel RL.

Per Med. 2018 May 1;15(3):199-208. doi: 10.2217/pme-2017-0077. Epub 2018 May 30.

27.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV.

Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.

28.

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.

Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, Azimi R, Rizvi H, Riess JW, Hellmann MD, Awad MM.

J Clin Oncol. 2018 Jul 1;36(19):1905-1912. doi: 10.1200/JCO.2017.77.0305. Epub 2018 May 10.

29.

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, Ni A, Novik JB, Mangarin LMB, Abu-Akeel M, Liu C, Sauter JL, Rekhtman N, Chang E, Callahan MK, Chaft JE, Voss MH, Tenet M, Li XM, Covello K, Renninger A, Vitazka P, Geese WJ, Borghaei H, Rudin CM, Antonia SJ, Swanton C, Hammerbacher J, Merghoub T, McGranahan N, Snyder A, Wolchok JD.

Cancer Cell. 2018 May 14;33(5):843-852.e4. doi: 10.1016/j.ccell.2018.03.018. Epub 2018 Apr 12.

30.

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.

Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, Rouche JA, Zitvogel L, Zalcman G, Albiges L, Escudier B, Routy B.

Ann Oncol. 2018 Jun 1;29(6):1437-1444. doi: 10.1093/annonc/mdy103.

31.

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, Riely GJ, Schultz N, Hellmann MD.

J Clin Oncol. 2018 Mar 1;36(7):633-641. doi: 10.1200/JCO.2017.75.3384. Epub 2018 Jan 16. Erratum in: J Clin Oncol. 2018 Jun 1;36(16):1645.

32.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

PMID:
29097494
33.

Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.

Kaunitz GJ, Loss M, Rizvi H, Ravi S, Cuda JD, Bleich KB, Esandrio J, Sander I, Le DT, Diaz LA Jr, Brahmer JR, Drake CG, Hollmann TJ, Lacouture ME, Hellmann MD, Lipson EJ, Taube JM.

Am J Surg Pathol. 2017 Oct;41(10):1381-1389. doi: 10.1097/PAS.0000000000000900.

34.

Ulcerated nodules in the groin of an immunosuppressed patient.

Nasir S, Van De Velde V, Rizvi H, Cerio R, Nic Fhogartaigh C, Jolliffe V, Harwood C.

Clin Exp Dermatol. 2017 Jul;42(5):558-560. doi: 10.1111/ced.13095. Epub 2017 Jun 7. No abstract available.

PMID:
28589546
35.

Nivolumab induced myxedema crisis.

Khan U, Rizvi H, Sano D, Chiu J, Hadid T.

J Immunother Cancer. 2017 Feb 21;5:13. doi: 10.1186/s40425-017-0213-x. eCollection 2017.

36.

Sweet syndrome: a painful reality.

Khan U, Rizvi H, Ali F, Lebovic D.

BMJ Case Rep. 2016 Dec 23;2016. pii: bcr2016217606. doi: 10.1136/bcr-2016-217606.

37.

Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.

Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok JD, Merghoub T, Rudin CM, Fish S, Hellmann MD.

Ann Oncol. 2017 Mar 1;28(3):583-589. doi: 10.1093/annonc/mdw640.

38.

Hybrid boron nitride-natural fiber composites for enhanced thermal conductivity.

Xia C, Garcia AC, Shi SQ, Qiu Y, Warner N, Wu Y, Cai L, Rizvi HR, D'Souza NA, Nie X.

Sci Rep. 2016 Oct 5;6:34726. doi: 10.1038/srep34726.

39.

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann MD.

J Clin Oncol. 2017 Mar;35(7):709-717. doi: 10.1200/JCO.2016.68.2005. Epub 2016 Sep 30. Erratum in: J Clin Oncol. 2017 Aug 1;35(22):2590.

40.

Interrelationship of serum S100B and P53 in brain tumour patients.

Syeda T, Rizvi HA, Hadi SM, M Hashim AS, Khan MH.

J Pak Med Assoc. 2016 Jun;66(6):748-50.

41.

Cadmium stress in rice: toxic effects, tolerance mechanisms, and management: a critical review.

Rizwan M, Ali S, Adrees M, Rizvi H, Zia-Ur-Rehman M, Hannan F, Qayyum MF, Hafeez F, Ok YS.

Environ Sci Pollut Res Int. 2016 Sep;23(18):17859-79. doi: 10.1007/s11356-016-6436-4. Epub 2016 Mar 21. Review.

PMID:
26996904
42.

Property enhancement of soy protein isolate-based films by introducing POSS.

Xia C, Zhang S, Shi SQ, Cai L, Garcia AC, Rizvi HR, D'Souza NA.

Int J Biol Macromol. 2016 Jan;82:168-73. doi: 10.1016/j.ijbiomac.2015.11.024. Epub 2015 Nov 14.

PMID:
26586590
43.

Microscopic Observation Drug Susceptibility Assay for Rapid Diagnosis of Lymph Node Tuberculosis and Detection of Drug Resistance.

Kirwan DE, Ugarte-Gil C, Gilman RH, Caviedes L, Rizvi H, Ticona E, Chavez G, Cabrera JL, Matos ED, Evans CA, Moore DA, Friedland JS; Lymph Node TB Working Group, Peru.

J Clin Microbiol. 2016 Jan;54(1):185-9. doi: 10.1128/JCM.02227-15. Epub 2015 Oct 28.

44.

United Kingdom immune thrombocytopenia registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings.

Rizvi H, Butler T, Calaminici M, Doobaree IU, Nandigam RC, Bennett D, Provan D, Newland AC.

Br J Haematol. 2015 May;169(4):590-4. doi: 10.1111/bjh.13330. Epub 2015 Mar 5.

PMID:
25753327
45.

Antitumor effects of hyaluronan inhibition in desmoid tumors.

Briggs A, Rosenberg L, Buie JD, Rizvi H, Bertagnolli MM, Cho NL.

Carcinogenesis. 2015 Feb;36(2):272-9. doi: 10.1093/carcin/bgu324. Epub 2015 Jan 2.

PMID:
25556151
46.

Generalized equilibrium problem with mixed relaxed monotonicity.

Rizvi HA, Kılıçman A, Ahmad R.

ScientificWorldJournal. 2014;2014:807324. doi: 10.1155/2014/807324. Epub 2014 Jul 10.

47.

Intracellular TCR-signaling pathway: novel markers for lymphoma diagnosis and potential therapeutic targets.

Agostinelli C, Rizvi H, Paterson J, Shende V, Akarca AU, Agostini E, Fuligni F, Righi S, Spagnolo S, Piccaluga PP, Clark EA, Pileri SA, Marafioti T.

Am J Surg Pathol. 2014 Oct;38(10):1349-59. doi: 10.1097/PAS.0000000000000309.

PMID:
25118816
48.

Pre- and post-operative values of serum CRP in patients undergoing surgery for brain tumour.

Syeda T, Hashim AS, Rizvi HA, Hadi SM.

J Pak Med Assoc. 2014 Mar;64(3):271-4.

49.

Influence of Pseudomonas aeruginosa as PGPR on oxidative stress tolerance in wheat under Zn stress.

Islam F, Yasmeen T, Ali Q, Ali S, Arif MS, Hussain S, Rizvi H.

Ecotoxicol Environ Saf. 2014 Jun;104:285-93. doi: 10.1016/j.ecoenv.2014.03.008. Epub 2014 Apr 15.

PMID:
24726941
50.

Lack of anti-tumor activity with the β-catenin expression inhibitor EZN-3892 in the C57BL/6J Min/+ model of intestinal carcinogenesis.

Hasson RM, Briggs A, Rizvi H, Carothers AM, Davids JS, Bertagnolli MM, Cho NL.

Biochem Biophys Res Commun. 2014 Feb 14;444(3):283-9. doi: 10.1016/j.bbrc.2013.11.135. Epub 2014 Jan 31.

PMID:
24486542

Supplemental Content

Support Center